Genzyme said it plans to buy Bone Care International, make it part of
Genzyme's U.S. renal operations and take advantage of the firm's $119
million cash on hand. Genzyme said it plans to register Bone Care's
Hectorol, for treating secondary hyperparathyroidism associated with
kidney dialysis, in other countries after it completes the estimated $600 million acquisition.